Jeanette M. Bjorkquist - 16 Feb 2023 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Role: Principal Accounting Officer
Signature: /s/ John O. Gunderson, as Attorney-in-Fact
Issuer symbol: ASMB
Transactions as of: 16 Feb 2023
Net transactions value: -$637
Form type: 4
Filing time: 31 Mar 2023, 16:40:08 UTC
Previous filing: 13 Sep 2022
Next filing: 24 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ASMB	Common Stock	Award	$0	+6,250	+34%	$0.000000	24,580	29 Mar 2023	Direct	F1, F2
transaction	ASMB	Common Stock	Sale	$637	-774	-3.1%	$0.8232	23,806	30 Mar 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ASMB	Stock Option (right to buy)	Award	$0	+2,000		$0.000000	2,000	16 Feb 2023	Common Stock	2,000	$1.53	Direct	F5
transaction	ASMB	Stock Option (right to buy)	Award	$0	+12,500		$0.000000	12,500	29 Mar 2023	Common Stock	12,500	$0.8900	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2024; March 29, 2025; March 29, 2026; and March 29, 2027.
F2	Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on November 14, 2022.
F3	The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7795 to $0.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
F5	Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, February 16, 2024; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on February 16, 2027.